Provention Bio, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PRVB research report →
About the company
Provention Bio, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and bringing to market therapies aimed at intercepting and preventing autoimmune disorders. Their lead investigational candidate, PRV-031 (teplizumab, a monoclonal antibody), is currently in a Phase III clinical trial for the interception of Type 1 Diabetes (T1D).
- CEO
- Ashleigh W. Palmer
- IPO
- 2018
- Employees
- 174
- HQ
- Red Bank, NJ, US
Price Chart
- Market Cap
- $2.38B
- P/E
- -16.43
- P/S
- 184.21
- P/B
- 15.32
- EV/EBITDA
- -18.89
- Div Yield
- 0.00%
- Gross Margin
- 96.03%
- Op Margin
- -993.88%
- Net Margin
- -880.69%
- ROE
- 133.43%
- ROIC
- -78.27%
- Revenue
- $12.89M · 824.37%
- Net Income
- $-113,565,000 · 0.76%
- EPS
- $-1.52 · 16.02%
- Op Income
- $-128,161,000
- FCF YoY
- 20.91%
- 52W High
- $25.00
- 52W Low
- $3.19
- 50D MA
- $19.10
- 200D MA
- $10.15
- Beta
- 2.46
- Avg Volume
- 2.84M
Get TickerSpark's AI analysis on PRVB
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 27, 23 | Sessa Capital (Master), L.P. | other | 15,567,497 |
| Apr 27, 23 | Wysenski Nancy | sell | 128,981 |
| Apr 27, 23 | Wysenski Nancy | sell | 22,200 |
| Apr 27, 23 | Wysenski Nancy | sell | 23,000 |
| Apr 27, 23 | Wysenski Nancy | sell | 33,000 |
| Apr 27, 23 | Pisano Wayne | sell | 33,000 |
| Apr 27, 23 | Pisano Wayne | sell | 23,000 |
| Apr 27, 23 | Pisano Wayne | sell | 24,000 |
| Apr 27, 23 | Pisano Wayne | sell | 128,981 |
| Apr 27, 23 | Pisano Wayne | sell | 22,200 |
Our PRVB coverage
Recent articles, reports, and earnings notes.
No research on PRVB yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PRVB report →Similar companies
Peers in the same neighborhood.